The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.
This aims to collect observational data that describe clinical (primary endpoint) and subclinical (secondary endpoint) cardiopulmonary toxicities from combined thoracic radiotherapy and immunotherapy up to 25 months after thoracic radiotherapy and 12 months after consolidation immunotherapy among patients with locally advanced lung cancer.
Study Type
OBSERVATIONAL
Enrollment
125
Radiation dose of 45 Gy or higher
checkpoint inhibitor per PI discretion
University of Missouri - Ellis Fischel Cancer Center
Columbia, Missouri, United States
RECRUITINGRutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
RECRUITINGUniversity of Rochester Medical Center
Rochester, New York, United States
RECRUITINGClinical cardiopulmonary toxicities
To determine clinical cardiopulmonary toxicities from standard RT and immunotherapy per CTCAEv5.0
Time frame: 25 months
subclinical/asymptomatic cardiopulmonary events
Asymptomatic cardiopulmonary events determined per abnormal lab values such as troponin and physiological testing
Time frame: 25 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.